Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

Tim R. Cressey; Rohan Hazra; Andrew Wiznia; Marc Foca; Patrick Jean-Philippe; Bobbie Graham; Jennifer R. King; Paula Britto; Vincent J. Carey; Edward P. Acosta; Ram Yogev

doi:10.1097/INF.0000000000001320

Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

Tim R. Cressey, Rohan Hazra, Andrew Wiznia, Marc Foca, Patrick Jean-Philippe, Bobbie Graham, Jennifer R. King, Paula Britto, Vincent J. Carey, Edward P. Acosta, Ram Yogev

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

Original language	English (US)
Pages (from-to)	1333-1335
Number of pages	3
Journal	Pediatric Infectious Disease Journal
Volume	35
Issue number	12
DOIs	https://doi.org/10.1097/INF.0000000000001320
State	Published - Nov 28 2016
Externally published	Yes

Keywords

Antiretrovirals
Atazanavir
Pediatrics
Pharmacokinetics

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/INF.0000000000001320

Cite this

Cressey, T. R., Hazra, R., Wiznia, A., Foca, M., Jean-Philippe, P., Graham, B., King, J. R., Britto, P., Carey, V. J., Acosta, E. P., & Yogev, R. (2016). Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults. Pediatric Infectious Disease Journal, 35(12), 1333-1335. https://doi.org/10.1097/INF.0000000000001320

@article{4c2dc1ae6f0440ce83026a0475e84b29,

title = "Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults",

abstract = "HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.",

keywords = "Antiretrovirals, Atazanavir, Pediatrics, Pharmacokinetics",

author = "Cressey, {Tim R.} and Rohan Hazra and Andrew Wiznia and Marc Foca and Patrick Jean-Philippe and Bobbie Graham and King, {Jennifer R.} and Paula Britto and Carey, {Vincent J.} and Acosta, {Edward P.} and Ram Yogev",

year = "2016",

month = nov,

day = "28",

doi = "10.1097/INF.0000000000001320",

language = "English (US)",

volume = "35",

pages = "1333--1335",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

AU - Cressey, Tim R.

AU - Hazra, Rohan

AU - Wiznia, Andrew

AU - Foca, Marc

AU - Jean-Philippe, Patrick

AU - Graham, Bobbie

AU - King, Jennifer R.

AU - Britto, Paula

AU - Carey, Vincent J.

AU - Acosta, Edward P.

AU - Yogev, Ram

PY - 2016/11/28

Y1 - 2016/11/28

N2 - HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

AB - HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

KW - Antiretrovirals

KW - Atazanavir

KW - Pediatrics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84984700603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984700603&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000001320

DO - 10.1097/INF.0000000000001320

M3 - Article

C2 - 27583590

AN - SCOPUS:84984700603

SN - 0891-3668

VL - 35

SP - 1333

EP - 1335

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 12

ER -

Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this